Floatz logo

Nirsevimab

Viral Respiratory Tract Infection

Explore 1 assets in Viral Respiratory Tract Infection →
Floatz Rating
BB65/100
Confidence
Indicative
v0.2
Sponsor
Menzies School of Health Research
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Indicative
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT07578298CT.gov
THRIVE - Trial of Passive Humoral RSV Immunity for Value and Effectiveness
—Not Yet Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.

Same indication · Viral Respiratory Tract Infection

AssetSponsorPhaseRating
Nirsevimab (this asset)Menzies School of Health ResearchApprovedBB · 65

Other indications for Nirsevimab

IndicationSponsorPhaseRating
Respiratory Syncytial Virus Infectious Disease—P4BB · 65

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Citation

Floatz Terminal. Nirsevimab in Viral Respiratory Tract Infection. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/nirsevimab-viral-respiratory-tract-infection

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →